Residual daytime effects of esmirtazapine

Citation:

Ivgy-May N. Residual daytime effects of esmirtazapine. J Clin Sleep Med. 2021;17(4):865.

We thank Sangal for his comment,¹ which made us realize that the wrong version of the supplemental material was posted on the website for our study.² The correct version has now been uploaded, and Figure S2 in our article now shows the results for the visual analog scales. These results are the basis for our statements concerning residual effects. We apologize for this error.

DISCLOSURE STATEMENT

Work for the study referenced in this letter was funded by Organon, a subsidiary of Akzo Nobel at the time of the study and subsequently a subsidiary of Merck & Co., Inc., Kenilworth, NJ. Neely Ivgy-May, Gonnie van Osta, and Qing Chang were employees of Organon, a subsidiary of Akzo Nobel at the time of the study and subsequently a subsidiary of Merck & Co., Inc., Kenilworth, NJ, and they may own stock and/or stock options. Sabine Braat was an employee of Organon, a subsidiary of Akzo Nobel, at the time of the study. All other authors reported no conflicts of interest outside of the submitted work. At the time of the study, Neely Ivgy-May was affiliated with Merck & Co., Inc., Kenilworth, NJ. She is currently affiliated with Taisho Pharmaceutical R&D Inc., Morristown, NJ. At the time of the study, Gonnie van Osta was affiliated with Merck & Co., Inc., Kenilworth, NJ. She is currently affiliated with Data Analysis and Reporting, Hilversum, the Netherlands. At the time of the study, Sabine Braat was affiliated with MSD, Oss, the Netherlands. She is currently affiliated with the Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Australia.